Evidence map›Paper›PMID 39255191›Full record

ArticleeLife2024

Distinguishing mutants that resist drugs via different mechanisms by examining fitness tradeoffs.

Kara Schmidlin, Sam Apodaca, Daphne Newell, Alexander Sastokas, Grant Kinsler, Kerry Geiler-Samerotte

Abstract read
In one paragraph

Article in eLife, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Protein structure shapes natural genetic variation andbioRxiv : the preprint server for biology · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Epistasis-mediated compensatory evolution in a fitness landscape with adaptational tradeoffs.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Kara Schmidlin *Biodesign Center for Mechanisms of Evolution, Arizona State University, Tempe, United States.ORCID https://orcid.org/0000-0001-6892-0928
Sam Apodaca *Biodesign Center for Mechanisms of Evolution, Arizona State University, Tempe, United States.
Daphne NewellBiodesign Center for Mechanisms of Evolution, Arizona State University, Tempe, United States.
Alexander SastokasBiodesign Center for Mechanisms of Evolution, Arizona State University, Tempe, United States.
Grant KinslerDepartment of Bioengineering, University of Pennsylvania, Philadelphia, United States.ORCID https://orcid.org/0000-0001-8308-4665
Kerry Geiler-SamerotteBiodesign Center for Mechanisms of Evolution, Arizona State University, Tempe, United States.ORCID https://orcid.org/0000-0003-4666-2192

Funding

A quantitative examination of cellular mechanisms that modulate the impacts of genetic variation - Renewal - 1R35GM133674 · NIGMS · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI Kerry A Geiler-Samerotte · 2019 to 2026
$2.8M
Alfred P. Sloan Foundation FG-2021-15705National Science Foundation BII 2119963NIGMS NIH HHS R35 GM133674NIH HHS R35GM133674
6 · The paper itself

Abstract

There is growing interest in designing multidrug therapies that leverage tradeoffs to combat resistance. Tradeoffs are common in evolution and occur when, for example, resistance to one drug results in sensitivity to another. Major questions remain about the extent to which tradeoffs are reliable, specifically, whether the mutants that provide resistance to a given drug all suffer similar tradeoffs. This question is difficult because the drug-resistant mutants observed in the clinic, and even those evolved in controlled laboratory settings, are often biased towards those that provide large fitness benefits. Thus, the mutations (and mechanisms) that provide drug resistance may be more diverse than current data suggests. Here, we perform evolution experiments utilizing lineage-tracking to capture a fuller spectrum of mutations that give yeast cells a fitness advantage in fluconazole, a common antifungal drug. We then quantify fitness tradeoffs for each of 774 evolved mutants across 12 environments, finding these mutants group into classes with characteristically different tradeoffs. Their unique tradeoffs may imply that each group of mutants affects fitness through different underlying mechanisms. Some of the groupings we find are surprising. For example, we find some mutants that resist single drugs do not resist their combination, while others do. And some mutants to the same gene have different tradeoffs than others. These findings, on one hand, demonstrate the difficulty in relying on consistent or intuitive tradeoffs when designing multidrug treatments. On the other hand, by demonstrating that hundreds of adaptive mutations can be reduced to a few groups with characteristic tradeoffs, our findings may yet empower multidrug strategies that leverage tradeoffs to combat resistance. More generally speaking, by grouping mutants that likely affect fitness through similar underlying mechanisms, our work guides efforts to map the phenotypic effects of mutation.

Indexed as

Antifungal AgentsDrug Resistance, FungalFluconazoleGenetic FitnessMutationSaccharomyces cerevisiaeAntifungal AgentsFluconazoleadaptive convergencecollateral sensitivitycomputational biologydrug resistanceevolutionary biologyfitness seascapefitness tradeoffsgenotype-phenotype mapS. cerevisiaesystems biology

Identifiers

PMID39255191
PMCPMC11386965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.